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Abstract 
1 
2 
Background and Objectives 
3 
4 
5 The Göteborg randomised population-based prostate cancer screening trial demonstrated that Prostate Specific 
6 
7 Antigen (PSA) based screening reduces prostate cancer deaths compared with an age matched control group. 
8 
9 Utilising the prostate cancer detection rates from this study we have investigated the clinical and cost- 
10 
11 
effectiveness of a similar PSA-based screening strategy for an Australian population of men aged 50-69 years. 
12 
13 
14 Methods 
15 
16 
17 A decision model that incorporated Markov processes was developed from a health system perspective. The 
18 
19 base case scenario compared a population-based screening programme with current opportunistic screening 
20 
21 practices. Costs, utility values, treatment patterns and background mortality rates were derived from Australian 
22 
23 data. All costs were adjusted to reflect July 2015 Australian dollars. An alternative scenario compared 
24 
25 systematic with opportunistic screening but with optimisation of active surveillance (AS) uptake in both groups. 
26 
27 A discount rate of 5% for costs and benefits was utilised. Univariate and probabilistic sensitivity analyses were 
28 
29 performed to assess the effect of variable uncertainty on model outcomes. 
30 
31 
32 Results 
33 
34 
Our model very closely replicated the number of deaths from bothprostate cancer and background mortality in 
35 
36 
the Göteborg study. The incremental cost per quality-adjusted life-year (QALY) for PSA screeningwas 
37 
38 
$AU147,528. However, for years of life gained (LYGs) PSA based screening ($AU45,890/LYG) appeared more 
39 
40 
favourable. Our alternative scenario with optimised AS improved cost-utility to $AU45,881/QALY, with 
41 
42 
screening becoming cost-effective at a 92% AS uptake rate. Both modelled scenarios were most sensitive to the 
43 
44 
45 utility of patients before and after intervention, and the discount rate used. 
46 
47 
Conclusion 
48 
49 
50 PSA-based screening is not cost-effective compared to Australia’s assumed willingness to pay threshold of 
51 
52 $AU50,000/QALY. It appears more cost-effective if LYGs are used as the relevant outcome, and is more cost 
53 
54 effective than the established Australian breast cancer screening programme on this basis. Optimised utilisation 
55 
56 of AS increases the cost-effectiveness of prostate cancer screeningdramatically. 
57 
58 
59 Key Points for Decision Makers: 
60 
61 
62 
63 
64 
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 PSA-based prostate cancer screening is not cost effective in an Australianpopulation with current 
1 
2 treatment patterns. 
3 
4  Increased utilisation of active surveillance (AS) enhances the cost-effectiveness of prostatecancer 
5 
6 screening, with screening becoming cost-effective at high AS uptake rates. 
7 
8  At current Australian treatment patterns PC screening is more cost-effective than the current Australian 
9 
10 breast cancer screening programme. 
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has the longest follow-up and the most robust trial protocol with a standardised serum PSA threshold 
(2.5ng/mL) and test interval of two years for the duration of the trial. [8] 
The cost-effectiveness of prostate cancer screening has also been explored in numerous cost-effectiveness 
analyses (CEAs) which have produced widely varying results. No CEA to date, however, has used the findings 
of the Göteborg cohort, with most modelling the results of the 9 year follow-up data from the ERSPC, which 
had a significantly higher NNT.[9-11] 
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1. Introduction: 
1 
2 
Prostate cancer (PC) is currently the most commonly diagnosed cancer in Australia, after non-melanomatous 
3 
4 
skin cancer, with Australia and New Zealand having amongst the highest incidences in the world.[1, 2] 
5 
6 
7 PC deaths in Australia totalled 3294 in 2011, the last year for which data is available, making it the fourth most 
8 
9 common cause of death in Australian males, and the second most common cause of cancer related death after 
10 
11 
lung cancer.[3] PC mortality consequently outnumbers both breast (2,680) and sex specific bowel cancer deaths 
12 
13 
(2,219 deaths in men) both of which have established population based screening programmes.[3] 
14 
15 
16 Despite the documented burden of disease that PC presents, the Royal Australian College of General 
17 
18 Practioners’ (RACGP) guidelines currently recommend against discussing the subject of prostate cancer 
19 
20 screening unless the subject is raised by the patient themselves.[4] 
21 
22 
23 The RACGP cite the recent PSA based population screening studies of the Prostate, Lung, Colorectal and 
24 
25 Ovarian Cancer Screening Trial (PLCO) and the 2009 results of the European Randomised Study of Screening 
26 
27 for Prostate Cancer (ERSPC) as evidence of no mortality benefit for prostate specific antigen (PSA) based 
28 
29 prostate cancer screening. [4] However, both PLCO and ERSPC studies suffered from methodological 
30 
31 failures.[5] The PLCO suffered from a short screening period of only 6 years, a high proportion of randomised 
32 
33 patients (44%) having had a serum PSA performed in the last 3 years, and 52% of the control group receiving a 
34 
35 PSA test over the 6 year screening period. [6] Compared to the Göteborg trial, the ERSPC suffered from 
36 
37 heterogeneous, and on average higher, PSA thresholds (2.5-10ng/mL) and heterogeneous, and on average 
38 
39 longer, screening intervals (2-7 years) and shorter follow-up.[7, 8] 
40 
41 
42 The more recently published results of the Göteborg Randomised Population-based prostate-cancerscreening 
43 
44 trial have demonstrated the greatest survival benefit and lowest number needed to treat (NNT) of any of the PSA 
45 
46 screening trials.[8] Of the randomised controlled trials exploring PSA based population screening the Göteborg 
Active surveillance (AS), an approach of monitoring rather than immediately treating low risk PC, has been 
1 
2 
3 
4 
5 
6 
demonstrated to decrease the harm of overtreatment, whilst preserving the benefits of screening.[12] Decision 
analyses investigating the cost-effectiveness of AS protocols compared to primary intervention for low risk 
prostate cancer found that AS dominated primary intervention at all modelled time horizons.[13, 14] 
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7 
8 
9 
10 
11 1. Aim 
12 
13 
We aimed to investigate the predicted cost utility of a theoretical Australian PSA-based population screening 
14 
15 
programme. In our model, prostate cancer diagnoses were risk stratified, and any subsequent treatment based 
16 
17 
upon current Australian treatment patterns. The accumulated costs, utilities and cancer specific mortality rates 
18 
19 
between hypothetical screening and non-screening cohorts were recorded and compared. We aimed to compare 
20 
21 
two systematic screening strategies to current opportunistic screening practices: (i) a screening strategy where 
22 
23 
any cancer diagnoses would be treated in accordance with current Australian treatment patterns and (ii) an 
24 
25 
active surveillance-optimised strategy where anylow risk PC diagnoses were followed with an active 
26 
27 
surveillance protocol instead of receiving primary intervention until clinical disease progression. 
28 
29 
30 
31 
32 
33 2. Methodology 
34 
35 
36 
37 
38 
2.1 Study Population 
39 
40 
41 The model evaluated the outcomes of a uniformly distributed Australian male cohorts aged between 50-69 
42 
43 years. A uniform distribution was selected to better reflect the recruitment method of the Göteborg study, as 
44 
45 opposed to all men entering the model at a set age, as is commonly employed in other decision models.[9-11] 
46 
47 
48 
49 
50 
51 2.2 Screening Strategies 
52 
53 
The model assessed the cost-utility of two screening strategies for prostate cancer: strategy 1) Asystematic 
54 
55 
population screening strategy, with invitation for screening with a serum PSA test every 2 years, with any supra- 
56 
57 
threshold PSA tests offered a Trans-Rectal Ultrasound guided biopsy (TRUS); strategy 2) Opportunistic prostate 
58 
59 
60 cancer screening, representing current standard practice. 
61 
Two separate scenarios were created utilising the same two screening strategies. The first scenario, or base case, 
1 
2 
3 
4 
5 
6 
7 
8 
9 
compared both screening programmes with any subsequent prostate cancer diagnoses being treated in 
accordance with current Australian clinical practices, with treatment strategies determined by both cancer risk 
stratification and patient preference. The second scenario, or the AS-optimised model, differed inthat 
subsequent low risk prostate cancer diagnoses were all treated initially with AS instead of the majority of cases 
62 
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10 receiving primary intervention. Those on active surveillance that had PSA progression (PSA ≥10ng/mL) or PC 
11 
12 upgrading (Gleason score >6) on subsequent TRUS biopsy would proceed to definitive intervention based upon 
13 
14 their new risk stratification. 
15 
16 
17 
18 
19 
2.3 Markov Model Structure and Health States 
20 
21 
22 To investigate the cost-utility of a PSA based screening programme in a simulated Australian population we 
23 
24 built a decision model utilising Markov processes in TreeAge Pro 2014 software suite. (TreeAge Software Inc., 
25 
26 Williamstown, MA, USA) 
27 
28 
29 All men entered the model in a cancer-free/pre-diagnosis health state. Literature based probabilities sawmen 
30 
31 either remain 1) disease free, 2) die of background (non-PC) causes or diagnosed with 3) low-risk, 4) 
32 
33 intermediate-risk, 5) high-risk or 6) advanced (metastatic) PC. 
34 
35 
36 Following diagnosis of non-metastatic PC the patient would either undergo AS (surveillance with curative 
37 
38 intent, limited to those with low risk diagnoses), surgery, radiation or watchful waiting (WW; surveillance with 
39 
40 palliative intent, limited to those with a life expectancy less than 10 years or contraindications to curative 
41 
42 therapy). Curative treatment options were limited to the most commonly available Australian treatment options 
43 
44 of Radical Retro-pubic Prostatectomy (RRP) and External Beam Radiation Therapy (EBRT). Following 
45 
46 diagnosis and treatment men would stay in risk stratified post-treatment health states until natural deathor 
47 
48 development of metastatic disease. (Figure 1) 
49 
50 
51 In line with the Göteborg study, PSA screening would cease once a patient reached age 69 years, but they would 
52 
53 continue to cycle through the model.[8] A one year cycle length was selected to best represent the slow natural 
54 
55 history of PC. A 20 year time horizon was selected owing to the paucity of quality literature on both the natural 
56 
57 history of PC and EBRT failure rates after this length of time. 
58 
59 
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2.4.1 Model Inputs 
1 
2 
Electronic literature searches utilising PubMed, Ovid MEDLINE and The Cochrane Library were performed to 
3 
4 
select model inputs for transition probabilities, utilities and costs. Australian studies were preferentially selected 
5 
6 
when available and where follow-up was appropriate for the model timeline. Where Australian studies were 
7 
8 
unable to wholly cover the timeline of the model, they were synthesized with estimates from international 
9 
10 
11 literature with longer follow-up. Where Australian studies were wholly lacking, mostly in the case oftransition 
12 
13 probabilities, hand selection of the international literature was performed. Synthesized estimates were given 
14 
15 preference over estimates from individual series. Where systematic reviews were non-existent, individualpapers 
16 
17 were analysed, with those papers with protocols best representing current Australian practice, the largest 
18 
19 numbers of recruited patients and the longest follow-up, where appropriate, being selected. 
20 
21 
22 
23 
24 2.4.2 Probabilities 
25 
26 
27 Probabilities of diagnoses of low, intermediate, high risk and advanced disease were drawn from the cumulative 
28 
29 incidences for each diagnosis in both screening and control populations in the Göteborg study. [8] Yearly 
30 
31 incidence rates were then calculated for each disease state diagnosis after adjusting for age and mortality related 
32 
33 drop-out rates. Prostate cancer risk stratification in the Göteborg trial was based upon D’Amico’s 1998 
34 
35 classification for prostate cancer: Low risk - Gleason score on biopsy ≤6, PSA ≤10, clinical stage ≤T1a, 
36 
37 Intermediate risk – Gleason score ≤7, PSA ≤20, clinical stage ≤T2b, High risk – Gleason score >7, PSA >20, 
38 
39 clinical stage >T2b).[15] 
40 
41 
42 Current treatment practices for each PC risk classification were drawn from Australian data.[16, 17]Treatments 
43 
44 were limited to RRP, EBRT, WW and AS as these are the most universally available Australian treatment 
45 
46 options. AS was only an option for patients diagnosed with low risk disease, consistent with current European 
47 
48 Association of Urology guidelines and similar to those of the Prostate Cancer Foundation of Australia, which 
49 
50 allows very low volume Gleason 3+4 and PSA values of <20 ng/mL.[18, 19] (Table 1) In the basecase 
51 
52 (Scenario 1) the AS uptake rate was as per current Australian treatment patterns (15% of low-risk diagnoses), in 
53 
54 Scenario 2, all low risk diagnoses were treated with AS until clinical disease progression (serum PSA ≥10, or 
55 
56 Gleason score >6 on subsequent biopsy). 
57 
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Probability of progression to definitive therapy after entering the AS disease state was derived from a synthesis 
1 
2 based estimate of AS series, and was dependant on time spent in the disease state.[20] Progression rates inthe 
3 
4 short-term (5 year) were similar to rates from an Australian AS cohort.[17] 
5 
6 
A treatment threshold of equal or greater to 76 years old was selected as described in Campbell-Walsh Urology. 
7 
8 
At this age all patients currently in the AS health state would transition to the WW health state.[21] 
9 
10 
11 
Probabilities of disease recurrence for each risk stratification following definitive treatment were derived from 
12 
13 analysis of 6,652 D’Amico risk stratified men receiving PC therapy at a high volume centre.[22] 
14 
15 
16 Probability of disease progression to metastasis for those in watchful waiting disease states was drawn from the 
17 
18 Prostate Intervention Versus Observation Trial (PIVOT), being more contemporaneous (published 2012 vs 
19 
20 2002), with longer median follow-up (10 years vs 6.2) and having more participants in the observation arm (367 
21 
22 vs 349 men) than the next largest study published by Holmberg et al.[23, 24] 
23 
24 
25 Risk of progression to the advanced disease state following post-treatment recurrence was drawn froman 
26 
27 international study which followed 2,426 men with biochemical recurrence after RRP with a median follow-up 
28 
29 of 6.6 years.[25] 
30 
31 
32 Adjustment for the possibility of initial clinical under-staging of low risk disease was performed, utilizing the 
33 
34 results of the largest published prostatectomy specimen series of 626 patients meeting the strict Prostate Cancer 
35 
36 Research International: Active Surveillance (PRIAS) criteria.[26] 
37 
38 
Probabilities of background mortality were drawn from Australian Bureau of Statistics age related mortality 
39 
40 
rates, and adjustments made for age related prostate cancer specific death rates.[27, 28] Although there is 
41 
42 
evidence androgen deprivation therapy (ADT) might increase the rate of cardiovascular events, an increase in 
43 
44 
45 cardiovascular mortality has not been conclusively demonstrated conclusively with significant discordance in 
46 
47 results between published trials.[29-31] Additionally, in our model ADT was only initiated when metastases 
48 
49 were present, reflecting more conservative practice and resulting in lower total ADT exposure. As such, we did 
50 
51 not adjust the transition probability to non-cancer related death for those in the metastatic disease state. We also 
52 
53 did not adjust for peri-operative mortality in the RRP group, however, Björklund et al’s paper demonstrated that 
54 
55 the 90 day per-operative mortality in >22,000 men receiving RRP was lower than the age-matched cohort 
56 
57 (<0.2%).[32] 
46 
47 
48 
49 
50 
51 
state utility value was drawn from a combination of Australian and international studies. [36, 39] Smith et al’s 
Australian HRQoL study demonstrated a utility of 0.9 at initiation of androgen deprivation therapy, however 
follow-up was inadequate to assess the utility of terminal prostate cancer.[36] The utility of PC at its terminal 
52 
53 stage was drawn from Farkilla et al, which assessed HRQoL using multiple health instruments (15D, EQ-5D, 
54 
55 VAS, EORTC QLQ-C30) from which our utility value of terminal PC of 0.6 was synthesized.[39] The utilityof 
56 
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the advanced disease state thus fell from0.9 to 0.6 over a five year period to represent deteriorating wellbeing 
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2.4.3 Utility Values 
1 
2 
Health states were each assigned a utility value representing the health-related quality of life of anaverage 
3 
4 
patient inhabiting that disease state. All health state utility values were derived from Australian data where 
5 
6 
possible. (Table 2) 
7 
8 
9 PC screening has been criticised as increasing anxiety and reducing health related quality of life (HRQoL) 
10 
11 
during and after diagnosis.[4] However, in the Dutch and Finnish centres of the ERSPC it was shown that 
12 
13 
screening does not induce short termHRQoL effect.[33, 34] Even those patients who had false positive results 
14 
15 
tended to regard screening as a positive experience.[35] Likewise participating in an active surveillance protocol 
16 
17 
does not appear to impact HRQoL or increase anxiety when compared to controls, with participants’ HRQoL 
18 
19 
similar to age adjusted controls.[34, 36, 37] Utility scores were consequently unaffected by screening or AS in 
20 
21 
our model. 
22 
23 
24 We elected to use a single Australian study for our post-treatment utility scores. Smith et al. followed thesame 
25 
26 large cohort (1500) of 50-69 year old men for 3 years before and after definitive treatment, comparing their 
27 
28 utility directly against an age and pre-morbidity matched control cohort over the same three year period, using 
29 
30 the same health instrument. This study utilised the University of California, prostate cancer index, a validated 
31 
32 
instrument which includes all 12 components of the commonly used 12-item short form (SF-12) questionnaire. 
33 
34 
They demonstrated a relative utility value of 0.95 when compared to age-matched controls at 3 yearsfollowing 
35 
36 
treatment.[36] 
37 
38 
39 Despite widely ranging protocols for administration of androgen deprivation therapy our model conservatively 
40 
41 initiated its usage only when patients transitioned to the metastatic health state. Of the treatment options 
42 
43 androgen deprivation therapy is widely regarding as having the greatest effect on HRQoL, however, this may 
44 
45 reflect the poor baseline of patients selected for androgen deprivation therapy.[36, 38] The metastatic health 
with increasing burden of disease. This terminal illness health state utility is quite conservative compared to 
1 
2 other cost utility analyses.[10, 38] 
3 
4 
All utility values for disease-states listed above used above were not absolute values, but were multipliers for 
5 
6 
7 
8 
9 
10 
11 
12 
the age related baseline utility in a contemporary Australian male population.[40] 
2.4.4 Costs 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
2.5 Model Outcomes 
The primary model output was Quality Adjusted Life Years (QALYs) for each screening strategyover 20 years. 
Costs effectiveness was measured as an Incremental Cost Effectiveness Ratio (ICER) and expressed in 
$/QALY. Life Years Gained (LYG) was used as an alternative model output to allow comparison with other 
cost-analyses that did not use the QALY metric. 
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13 
14 
15 Costs were accumulated by both being in a specific disease state (state costs) as well discrete events (transition 
16 
17 costs), such as having surgery. 
18 
19 
A health system perspective was used to assign costs for screening, AS and treatment, as the model aims to 
20 
21 
approximate the costs of a government-run screening programme. Out of pocket and time costs forprogramme 
22 
23 
24 participants were therefore not included. Transition and state costings were derived from a combination of 
25 
26 Australian studies, Medicare Benefits Schedule (MBS), Pharmaceutical Benefits Scheme (PBS) and Australian 
27 
28 Refined – Diagnosis Related Groups (AR-DRGs). (Table 3) All costs were inflated to 10 July 2015 dollars using 
29 
30 annual inflation rates from the Reserve Bank of Australia. 
31 
32 
33 
34 
The cost of annual screening was calculated from the overall number of PSA blood tests and TRUS biopsies 
35 
36 
performed in the Göteborg study. A fractional annual test frequency per patient was calculated after adjusting 
37 
38 
for model dropout for either natural death or reaching the age limit of screening. The Australian costs of a serum 
39 
40 
PSA test and a TRUS biopsy, allowing for a 2% rate of post-TRUS sepsis were then used to arrive at thefinal 
41 
42 
cost of screening per man aged 50-69 in the screening cohort.[21] 
43 
44 
45 
All future costs, QALYs and LYGs were discounted 5% and compared to a societal willingness to pay (WTP) of 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
$50,000/QALY in line with Pharmaceutical Benefits Advisory Committee guidelines and a half-cyclecorrection 
was applied to all Markov processes. [41] Undiscounted QALYs and LYGs are also presented due to ongoing 
controversy regarding the discounting of future health outcomes, particularly for screening and prevention 
programmes.[42, 43] Cancer-specific mortalities, and interventions saved per 10,000 men was also used to 
compare treatment strategies. 
46 
47 simultaneously. Beta and gamma distributions were estimated for utility and costings values respectively from 
48 
49 normal distributions with standard deviations of 20% above and below the base case values. A combination of 
50 
51 Dirichlet and beta distributions were drawn for probability values based on their standard error values, as per 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
Table 1. 10,000 samples were drawn for each probabilistic sensitivity analysis. 
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15 
2.6.1 Univariant Sensitivity Analysis 
16 
17 
18 We conducted univariate sensitivity analyses of all probabilities, cost and utility values to determine the effect 
19 
20 of uncertainty of each variable upon the models output. All cost and utility values were varied 20% above and 
21 
22 below the base case value. Transition probabilities were varied within their 95% confidence intervals. 
23 
24 Simulations were also run with a lifelong timeline and a cohort start age of 50 to assess possible impact on 
25 
26 model outcomes. 
27 
28 
29 Univariate sensitivity analysis outside of the confidence intervals was performed for the probability of entering 
30 
31 the active surveillance health state following a diagnosis of low risk PC. This was done to determine what rate 
32 
33 of primary active surveillance was required in order to achieve an increase in QALYs at a sub-threshold WTP 
34 
35 value. 
36 
37 
38 
39 
40 
2.6.2 Probabilistic Sensitivity Analysis 
41 
42 
43 Multivariate probabilistic sensitivity analysis was performed for all variables in the both scenarios to assess 
44 
45 overall model uncertainty. A second order Monte Carlo analysis was performed with all variables drawn 
46 
47 In our active surveillance optimised scenario the screening programme generated higher incremental QALYs 
48 
49 
than Scenario 1 (base case), with an additional 0.01222 QALYs per patient when compared to theopportunistic 
50 
51 
screening group. The cost of screening was also lower than Scenario 1, with an additional cost of $560 per 
52 
53 
patient in the opportunistic screening group. This yielded an ICER for the AS-optimised screening scenario of 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
$45,882/QALY compared to opportunistic screening. (Table 4) 
With QALYs undiscounted an additional 0.0229 QALYS per patient were gained with the screening programme 
yielding an ICER of $24,483/QALY. 
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2.6.3 External validation 
1 
2 
In order to validate our models we ran our base case model with a 15 year time horizon and 9958 men in each 
3 
4 
arm, to simulate the follow-up and cohort numbers of the Göteborg. Our model very closely replicated the 
5 
6 
number of deaths from both prostate cancer and background mortality in the Göteborg study with 40 screening 
7 
8 
and 72 non-screening prostate cancer specific deaths, and 1791 screening and 1788 non-screening deathsfrom 
9 
10 
11 background mortality. This compares with 44 screening and 78 non-screening prostate cancer specificdeaths, 
12 
13 and 1937 screening and 1904 non-screening deaths from background mortality in the Göteborg study. 
14 
15 
16 
17 
18 3 Results 
19 
20 
21 3.1.1 Scenario 1 - Base case 
22 
23 
24 With conservative modelling our theoretical population screening programme base case yielded an additional 
25 
26 0.00554 QALYs per patient at 20 years for an incremental cost of $817 per patient when compared to the 
27 
28 control group, opportunistic prostate cancer detection. This yielded an Incremental Cost Effectiveness Ratio 
29 
30 (ICER) for screening of $147,528/QALY. 
31 
32 
With QALYs undiscounted an additional 0.01102 QALYs per patient were gained with the screening 
33 
34 
programme yielding an ICER of $74,165/QALY. 
35 
36 
37 With LYGs as the model output, screening yielded an additional 0.01781 LYGs per patient compared to current 
38 
39 screening practices. This yielded an ICER of $45,890/LYG. (Table 4) 
40 
41 
42 
43 
44 
45 3.1.2 Scenario 2 - Optimised Active Surveillance 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
When we varied the probability of entering the AS health state after a diagnosis of low-risk PC outside of its 
confidence intervals in Model 1 the screening arm became cost effective at an AS uptake rate of 91.9% 
assuming an acceptable threshold for cost-effectiveness of $AU50,000/QALY. (Figure 4) 
13 
 
 
Whilst the AS-optimised screening Scenario 2 dominated Scenario 1(base case) in which usual treatment 
1 
2 approaches were implemented, this increase in QALYs and reduction in cost compared to Scenario 1 came at 
3 
4 the expense of one additional prostate cancer specific death per 10,000 men in both screened and unscreened 
5 
6 cohorts. The number of interventions performed in both the screening (208 fewer RRP, 355 fewer EBRT) and 
7 
8 non-screening groups per 10,000 men (105 fewer RRP, 149 fewer EBRT) was significantly reduced. 
9 
10 
11 
12 
13 
3.2.1 Univariate Sensitivity Analyses 
14 
15 
16 Univariate sensitivity analyses of both modelled scenarios were dominated by utility following definitive 
17 
18 therapy, particularly for Model 1. Varying the post-definitive therapy utility co-efficient from 0.95 to 0.90 led to 
19 
20 net disutility for the entire screening cohort in Model 1, and resulted in the point estimate for Model 2 exceeding 
21 
22 the WTP threshold. (Table 5) 
23 
24 
25 After post-treatment utility the next most influential variables were, in order: age-related utility, discountrate 
26 
27 and the utility of advanced disease. Cost variability within 20% of the base case value had little effect onoverall 
28 
29 model output with almost all transition probabilities being more influential. Reducing the age of model entry to 
30 
31 50 years old, rather than utilising a uniformly distribution between ages 50-69, had the effect of reducingthe 
32 
33 value of the point estimates without affecting the outcomes of the modelled scenarios. Similarly, utilising a 
34 
35 lifelong timeline, as opposed to a 20 year time horizon resulted in lower point estimates without affecting 
36 
37 scenario outcome. Whilst varying model inputs universally affected the value of the point estimates, it rarely 
38 
39 affected the outcome; Scenario 1 remained cost in-effective and Scenario 2 remained cost-effective in most 
40 
41 simulations. Results of the 4 variables with the most influence on ICER in the univariate sensitivity analysis are 
42 
43 presented in Tornado diagrams (Figure 2 and 3) and the ICERs of the most influential variables are presented in 
44 
45 Table 4. 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
$45,890/LYG. It must be stressed that the seemingly large difference between the cost/QALY and cost/LYG is 
not due simply to patient disutility following treatment. Rather, as evidenced by the univariate sensitivity 
analysis, two of most influential model variables were the pre-morbid utility score and the discount rate of 
future outcomes/costs, consequently multiple lives needed to be extended in order to generate a single additional 
QALY. The cost-effectiveness of our model compares favourably with other CEAs, which have demonstrated 
highly variable results.[9] 
14 
 
 
3.2.2 Probabilistic Sensitivity Analyses 
1 
2 
Probabilistic sensitivity analysis was performed for base model (Scenario 1) in order to ascertain the proportion 
3 
4 
of simulations in which it proved cost-effective. Assuming a willingness-to-pay threshold of 
5 
6 
$AU50,000/QALY the base case model was cost effective in 38% of simulations, delivered improved QALYs at 
7 
8 
supra-threshold WTP in 38%, and decreased QALYs in 24.5% of simulations. (Figure 5) 
9 
10 
11 
For Scenario 2, Optimised Active Surveillance, the probabilistic sensitivity analysis demonstrated cost- 
12 
13 
effectiveness in 53% of all simulations, provided an increase in QALYs at a supra-threshold WTP in 27% of 
14 
15 
simulations and decreased QALYs in 19% of simulations. (Figure 6) 
16 
17 
18 A cost-effectiveness acceptability curve was plotted for scenario 2 to demonstrate the effect of increasing WTP 
19 
20 on the number of cost-effective iterations, at a WTP of $100,000/QALY screening was cost effective in 66% of 
21 
22 all iterations.  (Figure 7) 
23 
24 
25 
26 
27 
28 4.1 Discussion 
29 
30 
Our model is the first to explore the effectiveness and the cost of instituting a PSA-based populationscreening 
31 
32 
programme based on the results of the Göteborg Randomised Population-based prostate-cancer screening trial. 
33 
34 
Other CEAs to date have based their assumptions upon the results of the PLCO or ERSPC trials, however, the 
35 
36 
protocols of both trials were flawed.[5] 
37 
38 
39 In our base case scenario, screening was not found to be cost effective as although it increased QALYs, it did so 
40 
41 at an incremental cost of $147,528/QALY, which was well above our nominal willingness to pay(WTP) of 
42 
43 $50,000/QALY. 
44 
45 
46 When the results are viewed with a LYG metric the results appear more favourable, with a cost of 
Pataky et al., in an ERSPC-based Canadian micro-simulation study, found screening strategies cost between 
1 
2 
3 
4 
5 
6 
7 
8 
$27,000 - $54,000/LYG compared to non-screening strategies.[9] They also found that all strategies resulted in 
decreased QALYs for the screened population, however, this result was very sensitive to the utility values 
used.[9] 
An American CEA based upon the NNT of the ERSPC (48 men) found at 9 years follow-up that screening was 
47 
48 
49 
50 
51 
52 
53 
metric, a 5% discount rate at a 20 year time horizon PSA based screening was more cost-effectiveat 
$45,890/LYG. 
Similarly, no true cost-utility analyses of the established Australian colon cancer screening programme have 
54 
55 been performed, however, a CEA examining cost/LYG has been undertaken.[45] The projected cost of 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
$53,989/LYG, after adjustment to today’s dollars, was higher than for our prostate cancer model, however, the 
time horizon the authors in this study selected was only 10 years. [46] 
15 
 
 
9 
10 
11 not cost-effective based upon their societal WTP of $100,000/LYG.[11] However, they found that screening 
12 
13 became cost effective when the NNT was less than 21, which compares favourably with the Göteborg’s NNT of 
14 
15 12.[8, 11] 
16 
17 
Only one CEA is published that aims to model an Australian prostate cancer screening programme, and it is 
18 
19 
based upon the 9 year follow-up data from the ERSPC.[10] This model failed to demonstrate cost-utility for a 
20 
21 
population screening model in Australia, with a cost of $291,817/QALY at 10 years follow-up, however, this 
22 
23 
analysis disregards the role of active surveillance completely.[10] Furthermore, every man in thismodel 
24 
25 
diagnosed with PC assumed a 0.05 disutility and all lifetime treatment costs immediately. This model also 
26 
27 
arguably overestimates costs by assuming the cost accrual of 100% screening compliance while assuming the 
28 
29 
30 compliance-unadjusted mortality reduction of the ERSPC which had only 82% of screened men having at least 
31 
32 one PSA test, and 86% of men undergoing TRUS when recommended.[7] 
33 
34 
Whilst our model suggests population-based screening at current AS uptake rates is not cost-effectivewhen 
35 
36 
compared to Australia’s WTP, it does appear to compare favourably with established Australian screening 
37 
38 
programmes. BreastScreen Australia have not performed a comprehensive cost-utility analysis todirectly 
39 
40 
compare cost/QALY against.[44] They have, however, performed a CEA, with the Markov model output unit 
41 
42 
being cost per LYG. Similar to our model, BreastScreen Australia also focused on a population of 50-69 year 
43 
44 
olds, used a biennial screening test and a 5% discount rate for future costs and benefits. After adjusting for 
45 
46 
inflation, the estimated cost per LYG over a 20 year time horizon was $47,776/LYG.[44] Using the same LYG 
A long-standing criticism of PC screening is the over-diagnosis and consequent overtreatment of clinically 
1 
2 
3 
4 
5 
6 
7 
8 
9 
indolent cancers. [7] The increasing uptake of active surveillance internationally might facilitate separation 
between low-grade PC diagnosis and its treatment.[47, 48] There is an increasing body ofevidence 
demonstrating that active surveillance can decrease the harm of overtreatment whilst maintaining the mortality 
benefits of screening.[12, 49] Indeed, while the base case for our model was found not to be cost-effectivebased 
47 
48 
49 
50 
51 
52 
utilisation of AS as a treatment option are crucial to the cost-effectiveness of PSA based prostatecancer 
screening and essential in reducing screening-related harm.[53, 54] 
This difficulty in establishing a disconnection between PC diagnosis and treatment might be alleviated by the 53 
54 
increasing utilisation of multi-parametric Magnetic Resonance Imaging (mpMRI).[55]. MpMRI hasshown 55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
utility as a second line diagnostic tool in lieu of TRUS biopsy.[55] It allows preferential detection ofthose 
intermediate and high risk prostate cancers more likely to benefit from intervention, thereby avoiding detection 
16 
 
 
10 upon current Australian treatment preferences, the cost/QALY wasshown to decrease dramatically with 
11 
12 increased active surveillance utilisation. Other CEAs investigating the role of active surveillance in primary 
13 
14 prostate cancer treatment have demonstrated that AS both increased QALYs and decreased treatment costs 
15 
16 when compared to primary intervention.[13, 14] Koerber found that active surveillance dominated primary 
17 
18 intervention for low risk PC, with AS yielding both lower costs and higher QALYs across modelled time 
19 
20 horizons of 5, 15 and 30 years follow-up.[14] Orlendorf et al found that while AS yielded higherlifetime 
21 
22 treatment costs than primary intervention this was offset by increased QALYs, with AS being the more cost- 
23 
24 effective treatment.[20] Our study extends these promising findings to suggest the AS-optimised model maybe 
25 
26 cost-effective in the Australian setting. 
27 
28 
29 The AS uptake rate required for cost effectiveness in our model was 92%, which whilst high, may not be 
30 
31 unattainable. Data from the Victorian Prostate Cancer Registry (VPCR) demonstrates increasing AS utilisation 
32 
33 in recent years, with 36% of all new low risk diagnoses initially selecting AS.[50] In Sweden, AS is nowthe 
34 
35 most commonly selected primary treatment for low risk PC, with 72% of all new diagnoses initially managed 
36 
37 with AS.[51] 
38 
39 
40 Concerns about clinical under-grading and under-staging of prostate cancer exist and are perhaps contributingto 
41 
42 under-utilisation of AS as a treatment option for low risk prostate cancer.[26, 52] However, the clinical effect of 
43 
44 an initial under-grading of prostate cancer in AS patients is yet to be established and it is not reason enough to 
45 
46 deny patients the option of AS. The un-marrying of PC diagnosis and its immediate treatment and theincreased 
of cancers unlikely to be clinically significant.[55] A cost-effectiveness analysis in the Netherlands has 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
demonstrated similar costs for both mpMRI and TRUS pathways, but with a superior HRQoL in the mpMRI 
cohort due to reduced interventions for low risk disease.[56] In addition mpMRI has been demonstrated to aid 
correct risk stratification of patients prior to enrolment in an active surveillance protocol.[57] 
4.2 Limitations 
outcome. (Table 4) 47 
48 
49 Another limitation is the use of non-time dependant probabilities for disease recurrence post-treatment, andfor 
50 
51 development of metastases following disease recurrence. However, sensitivity analysis reveals the model to be 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
relatively insensitive to these variables, and consequently it is unlikely thisaffected model outcomes. 
The most significant limitation of our study compared to an actuarial population screening program is that the 
cohort of men that entered the model were aged between 50-69 in a uniform distribution to better parallel the 
recruitment method of the Göteborg study. A programme where all participants first underwent screening at age 
17 
 
 
12 
13 
14 Our study has several limitations. Firstly probabilities are drawn from a prostate cancer screening study 
15 
16 performed on a cohort of Swedish men. We did not adjust for Australia’s higher incidence of PC as this may 
17 
18 merely be an artefact of detection bias.[58] 
19 
20 
21 While we did account for immediate costs of complications for RRP, such as readmission within 30 days for 
22 
23 haematoma or infection, we did not account for cost of pads, incontinence surgeries or other treatment long-term 
24 
25 complication costs. However, analysis of post-procedure costs in the sensitivity analysis reveals this ishighly 
26 
27 unlikely to have had significant effect on the model’s outcome. 
28 
29 
30 Costs were not adjusted for societal costs of time off work for treatment, and likewise we did not adjust for loss 
31 
32 of ability to work from terminal disease. However, it is argued by many health economists that these time costs 
33 
34 exaggerate the true cost of a disease on the economy.[59] Our study was not intended to capture asocietal 
35 
36 perspective; therefore, it may have underestimated the total societal costs associated with screening, treatment, 
37 
38 or premature death. 
39 
40 
A further limitation is utilisation of a time horizon of 20 years instead of lifelong time horizon. As demonstrated 
41 
42 
in our sensitivityanalysis, a longer time horizon led to increased cost effectiveness in both models, particularly 
43 
44 
45 Scenario 1, although its ICER remained well above the WTP threshold, and as such did not change the decision 
46 
50 should allow earlier detection of prostate cancers and potentially increase the life years gained. When we ran 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
our model with a uniform entry age of 50 years old, the cost-effectiveness of both models improved (Table 4). 
However, as the diagnostic probabilities were drawn from Göteborg data and not age-stratified these resultsare 
unlikely to be representative of the true benefit of commencing screening earlier. 
Lastly, it should also be pointed out that the unscreened control cohort in the Göteborg study, whilst not 
formally invited to screening, were not PSA naïve, and still underwent a significant number of PSA tests and 11 
12 
13 TRUS biopsies as a part of random opportunistic screening. In this regard, the Göteborg study, and consequently 
46 
47 
48 
49 6. Compliance with Ethical Standards 
50 
51 
52 
53 
54 
55 
56 
57 
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60 
61 
62 
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65 
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This study was partially funded by a higher research scholarship from the Univeristy of Queensland (UQ). UQ 
did not have any influence on the subject matter of the study, model design or conclusions. No other external 
funding was received. 
18 
 
 
14 
15 our model, represents the benefits of a formal population screening program compared to a population exposed 
16 
17 to opportunistic screening only. In a truly unscreened, PSA naïve population, it is likely that the mortality 
18 
19 differences would be greater still, and the cost per additional QALY considerably more favourable. 
20 
21 
22 
23 
24 5. Conclusions 
25 
26 
27 Our model is a comprehensive cost-utility analysis of a theoretical PSA-based prostate cancerscreening 
28 
29 programme in Australia. In our base-case scenario prostate cancer population based screening with aninvitation 
30 
31 to participate every 2 years for men aged 50-69 years was not found to be cost effective when compared to a 
32 
33 commonly assumed willingness to pay threshold. It was, however, more cost effective per life year gained than 
34 
35 the current Australian population screening programme for breast cancer. When the scenario optimised 
36 
37 treatment post-diagnosis to focus on active surveillance, rather than primary intervention for low-riskdisease, 
38 
39 our screening model was cost-effective after 20 years of follow-up. PSA based population screening maybe 
40 
41 cost-effective when compared to opportunistic screening alone if low risk prostate cancer diagnoses can be 
42 
43 successfully uncoupled from primary definitive treatment. 
44 
45 
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8. Legends To Figures 
1 
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7 
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9 
10 
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12 
13 
Figure 1. Simplified state transition diagram demonstrating possible cancer diagnoses and treatment decisions 
that may be made, and subsequent disease states that may be entered by each simulated patient passing through 
the prostate cancer disease model. 
Figure 2. Incremental Cost Effectiveness Ratio (ICER) Tornado diagram of univariate sensitivity analysis of all 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
dollars per quality adjusted life year gained. ($AUD/QALY). 
23 
 
 
14 costs, probabilities and utility values in base case simulation (Scenario 1). The 4 most influential model 
15 
16 variables are presented. ICER is represented in Australia dollars per quality adjusted life year gained ($/QALY). 
17 
18 
19 Figure 3. Incremental Cost Effectiveness Ratio (ICER) Tornado diagram of univariate sensitivity analysis ofall 
20 
21 costs, probabilities and utility values in alternative model (Scenario 2). The 4 most influential model variables 
22 
23 are presented. ICER is represented in Australia dollars per quality adjusted life year gained ($/QALY). 
24 
25 
26 Figure 4. Primary Active Surveillance Rate for New Diagnoses of Low Risk Prostate Cancer versus Net 
27 
28 Monetary Benefits (NMB = expected QALYs x WTP - expected cost). Discount Rate 5%, Willingness To Pay 
29 
30 (WTP) of $50,000, modelled time horizon of 20 years. The screening model becomes cost effective at an active 
31 
32 surveillance uptake of 91.9%. 
33 
34 
Figure 5. Probabilistic Sensitivity Analysis Scatter Plot, Base Case Scenario (Scenario 1). Output in 
35 
36 
Incremental Cost Effectiveness, Screening Vs. No-Screening. 
37 
38 
39 Figure 6. Probabilistic Sensitivity Analysis Scatter Plot, Active Surveillance Optimised (Scenario 2) Output in 
40 
41 Incremental Cost Effectiveness, Screening Vs. No-Screening. 
42 
43 
44 Figure 7. Cost-Effectiveness Acceptability Curve, Active Surveillance Optimised (Scenario 2). Number of cost- 
45 
46 effective iterations versus societal Willingness To Pay (WTP). WTP varied between 0-$100,000 Australian 
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9.1 Table 1 Health State Transition Probabilities 
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State 
 
Event 
Transition 
probability 
 
Standard Error 
 
Source 
 
 
 
Screening 
Diagnosed Low Risk CaP 0.0045824791 0.0006770141 Hugosson, J. 2010[8] 
Diagnosed Intermediate Risk CaP 0.0027211009 0.0005221863 Hugosson, J. 2010[8] 
Diagnosed High Risk CaP 0.0007103095 2.67E-04 Hugosson, J. 2010[8] 
Diagnosed Advanced CaP 0.000339538 1.85E-04 Hugosson, J. 2010[8] 
 
 
 
Non-Screening 
Diagnosed Low Risk CaP 0.001567317 0.000396536 Hugosson, J. 2010[8] 
Diagnosed Intermediate Risk CaP 0.0019661929 0.0004440486 Hugosson, J. 2010[8] 
Diagnosed High Risk CaP 0.0009886531 3.15E-04 Hugosson, J. 2010[8] 
Diagnosed Advanced CaP 0.0006812806 2.62E-04 Hugosson, J. 2010[8] 
 
 
Diagnosed Low Risk 
CaP 
Proceed to EBRT 0.472 0.0352998584 Baade PD, 2012[60] 
Proceed to RRP 0.321 0.0330120433 Baade PD, 2012[60] 
Proceed to WW 0.057 0.0163937488 Baade PD, 2012[60] 
Proceed to AS #   
Diagnosed 
Intermediate Risk 
CaP 
Proceed to EBRT 0.4008127208 0.0205988903 Baade PD, 2012[60] 
Proceed to RRP 0.534 0.020967921 Baade PD, 2012[60] 
Proceed to WW #   
 
Diagnosed High Risk 
CaP 
Proceed to EBRT 0.4513333333 0.0374038546 
Baade PD, 2012[60] 
Proceed to RRP 0.452 0.0374087213 
Baade PD, 2012[60] 
Proceed to WW #   
 
 
 
 
 
Active Surveillance 
 
<76 years 
Develop Advanced Disease 
whilst on AS 
 
0.00523 
 
0.000425 
 
Koerber F 2014[14] 
Proceed to definitive treatment 
1st 5 years 
 
0.0643706623 
 
0.0077606108 
 
Orlendorf DA 2009[20] 
Proceed to definitive treatment 
2nd 5 years 
 
0.0323158832 
 
0.0055920986 
 
Orlendorf DA 2009[20] 
Proceed to definitive treatment 
3rd 5 years 
 
0.0188410491 
 
0.0042995423 
 
Orlendorf DA 2009[20] 
Active Surveillance 
 
≥76 years 
 
Proceed to WW 
 
1 
 
N/A 
Campbell-Walsh 
Urology[21] 
 
AS To Definitive 
Therapy 
Proceed to EBRT 0.2962962963 0.0367957508 Ischia JJ, 2012[17] 
Proceed to RRP 0.6296296296 0.0389135037 Ischia JJ, 2012[17] 
Proceed to WW #   
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1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 # = Sums to 1.0 with other probabilities in health state. 
34 
35 
36 CaP = Prostate Cancer 
37 
38 
RRP = Retro-pubic radical prostatectomy 
39 
40 
41 EBRT = External Beam Radiation Therapy 
42 
43 
44 WW = Watchful waiting 
45 
46 
AS = Active Surveillance 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
Clinical 
Understaging of Low 
Risk Disease 
Upstaged to Intermediate Risk 0.294 0.0182091154 El Hajj, A. 2013[26] 
 
Upstaged to High Risk 
 
0.206 
 
0.0161642923 
 
El Hajj, A. 2013[26] 
Post Treatment Low 
Risk 
 
Recurrence 
 
0.0112503069 
 
0.001293151 
 
Hernandez DJ, 2007[22] 
Post Treatment 
Intermediate Risk 
 
Recurrence 
 
0.0797437258 
 
0.0033214409 
 
Hernandez DJ, 2007[22] 
Post Treatment High 
Risk 
 
Recurrence 
 
0.1139901939 
 
0.0038965198 
 
Hernandez DJ, 2007[22] 
Post Treatment 
Recurrence 
 
Progress To Advanced Disease 
 
0.0127 
 
0.0016097136 
 
Boorjian SA, 2011[25] 
WW Low Risk 
Disease 
 
Progress To Advanced Disease 
 
0.0062604731 
 
0.0041172461 
 
Wilt TJ, 2012[24] 
WW Intermediate 
Risk Disease 
 
Progress To Advanced Disease 
 
0.0151549445 
 
0.0063771715 
Wilt TJ, 2012[24] 
WW High Risk 
Disease 
 
Progress To Advanced Disease 
 
0.024055818 
 
0.0079981496 
Wilt TJ, 2012[24] 
Advanced Disease Die of Advanced CaP 0.224 0.0045832217 PCTCG. 2000[61] 
 
ALL GROUPS 
 
Die Background Mortality 
 
Age dependant 
ABS Mortality rates, adjusted for age related 
prostate cancer mortality 
 
62 
63 
64 
65 
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9.2 Table 2 Health State Utility Values 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 *= Values are not absolute, but multipliers of the age dependant baseline utility value. 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
State Utility Source 
Baseline utility value Age dependant Banham D. 2014[40] 
Screening* 1 Vasarainen H. 2013[34] 
Non-Screening* 1 Vasarainen H. 2013[34] 
Post Treatment* 0.95 Smith DP. 2009[36] 
 
Advanced Disease* 
 
0.9->0.6 over 5 years 
Smith DP. 2009[36], Farkkila N. 
2014[39] 
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9.3 Table 3 Health State and Transition Costs 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
Event Cost Source 
Screening $34.89 Fractional cost of PSA tests + TRUS biopsy TOTAL per patient years in Göteborg[8] 
Diagnosis Cancer 
Screening 
$1,261.1 
0 
 
CT + Bone Scan + MBS item no. 104 + 105 
Diagnosis Cancer 
Non-Screening 
$1,873.5 
6 
 
PSA + TRUS + CT + Bone Scan + MBS item no. 104 + 105 
RRP $14,310 Hall R 2014[62] 
 
EBRT 
$15,977. 
 
48 
MBS item no. 104, 15550, 15562, 15705, 15248, 15263, calculated at 39 fractions, 6 fields + 
fractional cost of neoadjuvant hormones (.704, Baade PD, 2012[63]) 
AS $723.17 Fractional yearly cost of AS protocol over 4 years as per Yaxley J. 2013.[64] 
WW $161.00 105 x2, PSA x 2 
Cost Follow-Up 
Post Rx 
 
Time dependant, limit of 10 years: Year 1 (MBS 105+PSA)x4 Year 2-5 (MBS 105+PSA)x2 Year 
6-10 (MBS 105+PSA) 
Advanced Disease 
Year 1 
$5,773.5 
1 
 
Bicalutamide + Goserelin x 4 + 105 x2 + CT + Bone Scan 
Advanced Disease 
Year >1 
$4,672.0 
8 
 
Bicalutamide + Goserelin x 4 + 105 x2 
Prostate Cancer 
Death 
$28,000. 
 
00 
 
Carter H. 2014[65] 
Non-Prostate 
Cancer Death 
$19,430. 
 
62 
Canadian Non-Prostate Cancer Death ($36,028.92 Hollander MJ 2009[66])/Canadian Prostate 
Cancer Death($51,917.21 Krahn MD 2010[67]) X Australian Prostate Cancer Death ($28,000) 
ITEMS 
TRUS 
TRUS procedure $389.95 MBS item no. 37219 
Prostate Histology $210.35 MBS item no. 72827 
Ciprofloxacin $19.13 PBS DPMQ 
TRUS sepsis 
standard 
$5,276.0 
0 
 
AR-DRG codes 
 
TRUS sepsis severe 
$11,571. 
 
00 
 
AR-DRG codes 
TRUS sepsis rate 2% Campbell-Walsh Urology[21] 
TRUS TOTAL $737.71 TRUS + Histology + Ciprofloxacin + 0.02(0.9 TRUS standard + 0.1 TRUS severe) 
CT Abdomen/Pelvis $480.05 MBS item no. 56507 
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60 
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63 
64 
65 
28 
 
 
 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 CaP = Prostate Cancer 
21 
22 
RRP = Retro-pubic radical prostatectomy 
23 
24 
25 
EBRT = External Beam Radiation Therapy 
26 
27 
28 WW = Watchful waiting 
29 
30 
31 AS = Active Surveillance 
32 
33 
CT = Computerised Tomography 
34 
35 
36 TRUS = Trans-Rectal Ultrasound guided prostate biopsy 
37 
38 
39 
40 
41 
42 
43 
44 
45 
Tc99m Bone Scan $489.70 MBS item no. 61441 
Initital specialist 
consultation 
 
$85.55 
 
MBS item no. 104 
Review specialist 
consultation 
 
$43.00 
 
MBS item no. 105 
PSA $37.55 MBS item no. 66660 
Androgen Deprivation Therapy (ADT) 
Bicalutamide $131.68 PBS DPMQ 
 
Goserelin 
$1,108.9 
7 
 
PBS DPMQ 
Neoadjuvant 
hormones 
 
$2349.62 
 
Bicalutamide x1 + Goserelin x 2 
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62 
63 
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9.4 Table 4: Results 
 
 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
 Cost ($) QALYs LYG Cancer 
deaths/10,000 
men 
Non-Cancer 
deaths/10000 men 
MODEL 1: Basecase (20 years, 5% discount for both cost and utility) 
Control $4,664.17 9.32618 11.58002 98 2809 
Screening $5,481.47 9.33172 11.59783 59 2816 
Incremental $817.30 0.00554 0.01781 -39 7 
ICER $147,528/QALY $45,890/LYG  
MODEL 2: Optimised AS (20 years, 5% discount for both cost and utility) 
Control $4,524.92 9.32974 11.57838 99 2809 
Screening $5,085.59 9.34196 11.59619 60 2816 
Incremental $560.67 0.01222 0.01781 -39 7 
ICER $45,882/QALY $31,840/LYG  
MODEL 1: Basecase No discount on utilities. 5% discount on costs. 
Control $4,664.17 13.78585 17.6445 98 2809 
Screening $5,481.47 13.79692 17.6788 59 2816 
Incremental $817.30 0.01107 0.0343 -39 7 
ICER $103,965/QALY $23,828/LYG  
MODEL 2: Optimised AS No discount on utilities. 5% discount on costs. 
Control $4,524.92 13.79227 17.6446 99 2809 
Screening $5,085.59 13.81517 17.67908 60 2816 
Incremental $560.67 0.0229 0.03448 -39 7 
ICER $24,483.41/QALY $16,261/LYG  
 
9.5 Table 5: Sensitivity Analysis 
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15 
16 
17 
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19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
Variables New ICER 
Discount Rates MODEL 1 MODEL 2 
2% Discount for both $122,711/QALY $40,193/QALY 
8% Discount for both $177,932/QALY $50,664/QALY 
Utility  
Starting Utility 1.0 (Rather than age related) $103,957/QALY $33,021/QALY 
Utility Post- Treatment 0.9 Net dis-utility for screening 
cohort 
$58,010/QALY 
Timeline  
Lifelong timeline $103,565/QALY $38,553/QALY 
Age of model entry  
All patients start screening at 50 $109,898/QALY $37,967/QALY 
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